Content developed by Marie Fuzzati (IRCCS Mondino Foundation and France Parkinson) and Ludivine Breger (INSERM), in close collaboration with MIUR. For more information or for questions, please contact experimentalmodels@jpnd.eu.

General Information

Mice: C57BL/6

The human LRRK2 protein is expressed under the control of a mini version of the neuronal specific promoter Thy1.2.

Endogenous LRRK2: yes

Corresponding human genotype: LRRK2 is a major known genetic contributor to Parkinson’s disease.

Transgene expression

4 and 11 months: The total level of LRRK2 protein is 2 times higher than the level measured in the brain of non-transgenic animals. Expression is found at high level in the cortex and hippocampus but no expression of the human LRRK2 protein is detected in the SN.

Neurodegeneration

12-13 months: No obvious neurodegeneration is observed in the SN.

Dopamine Homeostasis

Not reported

Inclusions

11 months: No differences in the levels of alpha-synuclein are observed in the brain of transgenic animals.

Motor Behaviours

Not reported

Response to dopaminergic treatment

Not reported

Non-motor Behaviours

Not reported

Electrophysiology

Not reported

Neuroinflammation

Not reported

The EU Joint Programme – Neurodegenerative Disease Research (JPND) is the largest global research initiative aimed at tackling the challenge of neurodegenerative diseases, in particular Alzheimer’s. Learn More